bioRxivCancer Biology
Division of labor between YAP and TAZ in non-small cell lung cancer
M. Shreberk-Shaked, B. Dassa, S. Sinha, S. Di Agostino, I. Azuri, Y. Aylon, G. Blandino, E. Ruppin, M. Oren
Abstract
Lung cancer is the leading cause of cancer-related deaths worldwide. The paralogous transcriptional cofactors Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ, also called WWTR1), the main downstream effectors of the Hippo signal transduction pathway, are emerging as pivotal determinants of malignancy in lung cancer. Traditionally, studies have tended to consider YAP and TAZ as functionally redundant transcriptional cofactors, with similar biological impact. However, there is growing evidence that each of them also possesses distinct attributes. Here, we sought to systematically characterize the division of labor between YAP and TAZ in non-small cell lung cancer (NSCLC), the most common histological subtype of lung cancer. Employing representative NSCLC cell lines, as well as patient-derived data, we show that the two paralogs orchestrate non-overlapping transcription programs in this cancer type: whereas YAP preferentially regulates gene sets associated with cell division and cell cycle progression, TAZ preferentially regulates genes associated with extracellular matrix organization. Concordantly, depletion of YAP, but not TAZ, leads to growth arrest, while YAP overexpression promotes cell proliferation. Likewise, depletion of TAZ, but not YAP, compromises cell migration, whereas TAZ overexpression enhances migration. Importantly, the differential effects of YAP vs TAZ on key cellular processes are also associated with differential response to anti-cancer therapies. Uncovering the different activities and downstream effects of YAP and TAZ may thus facilitate better stratification of lung cancer patients for anti-cancer therapies.
- organism: human
- assay: bulk RNA-seq
- research focus: cell type annotation
- research focus: differential expression
- research focus: cell signaling & trafficking
- research focus: cancer & tumor microenvironment
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- YAP/TAZ and EZH2 synergize to impair tumor suppressor activity of TGFBR2 in non-small cell lung cancer
Federica Lo Sardo, Claudio Pulito, … Giovanni Blandino·bioRxiv·Jul 10, 2020
- Phosphodiesterase 1A physically interacts with YTHDF2 and reinforces the progression of non-small cell lung cancer
Chong Zhang, Zuoyan Zhang, … Yang-ling Li·eLifePeer-reviewed·Oct 15, 2024
- A noncanonical repressor function of JUN restrains YAP activity and suppresses YAP-dependent liver cancer growth
Yuliya V. Kurlishchuk, Anita Cindric Vranesic, … Björn von Eyß·bioRxiv·Aug 20, 2023
- YAP1 Depletion Enhances TAZ and its Complexation with TEAD4 and AP-1 Heterodimer C-JUN/FOSB to Promote Gastric Cancer Progression and Metastases
Jingjing Wu, Dipti Athavale, … Shumei Song·bioRxiv·Nov 13, 2025
- A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer
F. Haderk, C. Fernandez-Mendez, … T. G. Bivona·bioRxiv·Oct 23, 2021
- Transient YAP/TAZ inhibition exposes therapeutic vulnerabilities in advanced cancers
Marco Jessen, KyungMok Kim, … Björn von Eyß·bioRxiv·Jul 3, 2025